[Form 3] PURPLE BIOTECH LTD. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. director Simcha Rock filed an initial ownership statement showing substantial equity-based compensation. He directly holds 3,207,690 Ordinary Shares, including 2,454,167 unvested restricted stock units that settle in shares. He also holds stock options to buy 300,000 shares at $0.059375 per share and 2,650,000 shares at $0.00309375 per share, with vesting schedules running through 2028 and expirations in 2028 and 2030. Each American Depositary Share currently represents 2,000 Ordinary Shares.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Rock Simcha

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 300,000 shares (Direct); Ordinary Shares — 3,207,690 shares (Direct)

Footnotes (1)

1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rock Simcha

(Last) (First) (Middle)

4 OPPENHEIMER STREET

(Street)

SCIENCE PARK, REHOVOT 7670104

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,207,690(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	(2)	Ordinary Shares	300,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	2,650,000	(3)	D

Explanation of Responses:

1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

2. Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.

3. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.

	/s/ Simcha Rock	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)